<DOC>
	<DOCNO>NCT01509560</DOCNO>
	<brief_summary>In prospective study examine whether use everolimus patient allogeneic SCT part GVHD prophylaxis review clinical study appropriate .</brief_summary>
	<brief_title>PhaseII , Open-label , Pilot Study Evaluating Safety+Efficacy Certican ® Prevention Chronic Graft-versus-host Disease+Late Pulmonary Complications After Allogeneic Hematopoietic Cell Transplantation Blood</brief_title>
	<detailed_description />
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients allogeneic stem cell transplantation age ≥ 18 year Prophylaxes GvHD calcineurin inhibitor ( Ciclosporine A , Tacrolimus ) MTX MMF ( previous therapy acute GvHD additional prednisone permit ) Increased risk chronic GvHD , define Male female donor HLA mismatch class I II towards GvHD Persistant active acute GvHD day +50 stem cell transplantation despite highdose steroid cyclosporine Reduction baseline FEV1 DLCO ( examine 0 50 day transplantation ) ≥ 25 % New occurrence acute GvHD day +50 +100 stem cell transplantation Informed concent Use ( prophylactic therapeutic ) mTor inhibitor SCT Overlap acute chronic GvHD Total cholesterol ≥ 3fold upper limit ( UL ) triglycerides ≥ 3fold UL GOT , GPT , Bilirubin ≥ 3fold UL ( related GvHD ) Creatinine ≥ 3fold UL Confirmed active hepatitis B C All circumstance impair wound heal might risk factor , esp . surgical intervention last week , ulcer skin mucosa Known intolerance Everolimus , Sirolimus compoments Certican® Lactose intolerance Pregnancy lactation Women reproductive age , except woman follow criterion : Postmenopausal ( 12 month natural amenorrhea ) Postoperativ ( ≥ 6 month bilateral ovariectomy / without hysterectomy ) During therapy least 6 month last application Everolimus : regular correct higheffective contraception ( PearlIndex &lt; 1 ; e. g. oral contraception , intrauterine device , implantate , contraceptive patch , combination barrier method ( condom cervical cap/diaphragm ) , abstinence Men , use one follow method contraception therapy least 6 month last application Everolimus : Sexual abstinence Vasectomy Condom Impairments diseases reduce ability inform consent Participation another study ( e.g . prophylactic immunsuppression stem cell transplantation procedure ) within last 60 day recruitment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>